Comparative analysis of large language models: ChatGPT and Google Bard answer nonexpert questions related to the diagnostic and therapeutic applications of prostate-specific membrane antigen (PSMA) in patients with prostate cancer

被引：0
|
作者：
Hong, Julie [1 ]
Calais, Jeremie [1 ]
Benz, Matthias [1 ]
Auerbach, Martin
Salavati, Ali [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242416
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.
    Conteduca, Vincenza
    Oromendia, Clara
    Vlachostergios, Panagiotis J.
    Hackett, Amy
    Thomas, Charlene
    Case, Aidan
    Manohar, Jyothi
    Eng, Kenneth
    Sboner, Andrea
    Ballman, Karla V.
    Elemento, Olivier
    Nanus, David M.
    Beltran, Himisha
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [22] Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?
    Waechter, Sabine
    Di Fazio, Pietro
    Maurer, Elisabeth
    Manoharan, Jerena
    Keber, Corinna
    Pfestroff, Andreas
    Librizzi, Damiano
    Bartsch, Detlef K.
    Luster, Markus
    Eilsberger, Friederike
    CANCERS, 2021, 13 (22)
  • [23] The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease
    Evans, James C.
    Malhotra, Meenakshi
    Cryan, John F.
    O'Driscoll, Caitriona M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (21) : 3145 - U108
  • [24] Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
    de Kouchkovsky, Ivan
    Zhang, Li
    Huang, Jiaoti
    Trepka, Kai
    Chou, Jonathan
    Foye, Adam
    Shui, David
    Wong, Chris
    Friedl, Verena
    Weinstein, Alana
    Hope, Thomas A.
    Quigley, David A.
    Stuart, Josh
    Beer, Tomasz M.
    Reiter, Robert Evan
    Gleave, Martin E.
    Evans, Christopher P.
    Feng, Felix Y.
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] Comparison of [18F]DCFPyL Analogues Targeting Prostate-Specific Membrane Antigen (PSMA) in Human Prostate Cancer Xenograft (PCaX) Mouse Models
    Phelps, Tim
    Roy, Jyoti
    Basuli, Falguni
    Zhang, Xiang
    White, Margaret
    Wong, Karen
    Ton, Anita
    Woodroofe, Carolyn
    Swenson, Rolf
    Choyke, Peter
    Jagoda, Elaine
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [26] More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond
    Hyvakka, Anniina
    Virtanen, Verneri
    Kemppainen, Jukka
    Gronroos, Tove J.
    Minn, Heikki
    Sundvall, Maria
    CANCERS, 2021, 13 (09)
  • [27] The Role of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography in the Management of Patients With Prostate Cancer: Implications for Selection of Patients for Radiation Therapy
    Amit, U.
    Goldstein, J. D.
    Davidson, T.
    Hahiashvili, M.
    Goshen, E.
    Oksman, Y.
    Berger, R.
    Saad, A.
    Sadetsky, I.
    Chikman, B.
    Lawrence, Y. R.
    Ben-Haim, S.
    Symon, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S112 - S113
  • [28] Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Slovin, Susan F.
    Wang, Xiuyan
    Hullings, Melanie
    Arauz, Gabrielle
    Bartido, Shirley
    Lewis, Jason Stuart
    Schoeder, Heiko
    Zanzonico, Pat
    Scher, Howard I.
    Sadelain, Michel
    Riviere, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Daro-PET: A phase 2 trial of darolutamide as a prostate-specific membrane antigen (PSMA) expression enhancer in patients with localized prostate cancer.
    Mauricio, Jose
    Mosci, Camila
    Vasconcellos, Jessica
    Hemerly, Thiago Souto
    Silva Neto, Deusdedit Cortez Vieira
    Brandao, Luis Felipe
    Srougi, Victor
    Ramos, Rodrigo Nalio
    Cunha, Isabela Werneck
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS348 - TPS348
  • [30] Tumor models for PET-imaging of prostate and breast cancer targeting prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPr)
    Liolios, C.
    Roscher, M.
    Patsis, C.
    Bauder-Wuest, U.
    Eder, M.
    Kopka, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S238 - S239
12345